In a significant advancement for the field of oncology and molecular biology, investigators at the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins Bloomberg School of Public Health have identified the precise mechanism by which certain rearranged genes drive the progression of a rare and aggressive form of kidney cancer. The study, published on April 22 in the journal Cell Reports, reveals that proteins produced by these "fusion genes" aggregate into tiny liquid droplets within the cell nucleus. These droplets, known as condensates, act as command centers that systematically activate genes responsible for cancer growth and metastasis while silencing those that might otherwise inhibit tumor progression.
This discovery provides a long-sought explanation for the behavior of translocation renal cell carcinoma (tRCC), a subtype of kidney cancer that has historically lacked a standardized treatment protocol and often proves resistant to conventional therapies. By demonstrating that disrupting these liquid droplets can effectively "turn off" the cancer-driving genetic program, the research team has opened a promising new avenue for therapeutic intervention that could extend far beyond kidney cancer to other malignancies driven by similar genetic fusions.
The Molecular Architecture of Translocation Renal Cell Carcinoma
Translocation renal cell carcinoma is a distinct clinicopathological entity characterized by chromosomal translocations involving the TFE3 gene. While traditional renal cell carcinoma (RCC) typically involves different genetic pathways, such as the VHL mutation, tRCC occurs when a chromosome breaks and reattaches in a way that fuses the TFE3 gene with one of several partner genes, including PRCC, NONO, and SFPQ.
This genetic "swapping" creates a chimeric or fusion gene that produces a TFE3 fusion protein. While these proteins have been known to be the primary drivers of tRCC for years, the exact biophysical process by which they manipulated the cell’s internal machinery remained elusive until now.
Dr. Danfeng "Dani" Cai, an assistant professor of biochemistry and molecular biology at the Johns Hopkins Bloomberg School of Public Health and the study’s senior author, noted that the research focused heavily on the two most prevalent fusion partners: NONO and SFPQ. Together, these two variants account for approximately 40% of all TFE3 fusions observed in clinical settings.
"Individually, all the protein components found in the TFE3 fusions, including full-length TFE3, NONO, and SFPQ, are typically involved in the cell machinery that turns on genes to make proteins," Dr. Cai explained. "However, we found when in the form of these fusion proteins, they acquire an even stronger ability to control what genes get turned on."
Liquid-Liquid Phase Separation: The "Droplet" Mechanism
The core of the team’s discovery lies in a biological phenomenon known as liquid-liquid phase separation. This process allows cells to organize their internal environment without the use of membranes. Much like oil droplets forming in water, certain proteins and RNA molecules can cluster together to form "condensates"—concentrated hubs where specific biochemical reactions are accelerated.
To observe this in action, Dr. Cai’s team utilized advanced microscopy techniques. They attached fluorescent "tags" to the TFE3 fusion proteins within cells derived from kidney cancer patients. Under the microscope, these proteins did not distribute evenly throughout the nucleus; instead, they coalesced into distinct, glowing dots.
Further investigation revealed that these dots were not static structures but dynamic liquid condensates. Inside these droplets, the researchers identified the presence of marker proteins associated with active gene transcription, as well as the specialized proteins responsible for "reading" DNA and converting it into instructions for the cell. This confirmed that the droplets were serving as high-efficiency factories for cancer-promoting genetic activity.
Redesigning the Chromatin Landscape
To understand how these droplets interact with the human genome, Dr. Cai collaborated with Dr. Eneda Toska, an assistant professor of oncology at the Johns Hopkins Kimmel Cancer Center. Their joint effort focused on the "chromatin landscape"—the complex structure of DNA and proteins that determines which genes are accessible to the cell’s machinery.
DNA is typically packaged into chromatin, which scientists often describe as "beads on a string." When the string is tightly wound around the beads (nucleosomes), the genes are effectively locked away and "turned off." Conversely, when the string is open and accessible, the genes can be "turned on."
The research team found that the TFE3 fusion proteins do more than just sit on the DNA; they actively remodel it. "We found that these fusion proteins open and close different sites on the chromatin by making chemical modifications," said Dr. Toska. "They bind, regulate, and redesign the chromosome landscape, interacting with target genes that promote cell proliferation and movement—functions that cancer needs to grow and spread."
By altering the epigenetic state of the cell, these fusion proteins create a "permissive" environment for oncogenes—genes that drive cancer—while physically blocking the activation of genes that would normally trigger cell death or prevent uncontrolled division.
Identifying the "Coiled-Coil" Weakness
A pivotal moment in the study occurred when the researchers began "dissecting" the TFE3 fusion proteins to identify which specific segments were responsible for forming the liquid droplets. Using CRISPR-based gene editing and protein engineering, the team systematically removed different parts of the fusion protein.
They discovered that a small segment known as a "coiled-coil" domain—a structural motif where alpha-helices wrap around each other like the strands of a rope—was the essential "glue" for the condensates. When this coiled-coil segment was removed, the TFE3 fusion proteins lost their ability to form liquid droplets.
Crucially, without the droplets, the proteins could no longer activate the cancer-promoting genes, even though the rest of the protein remained intact. This finding suggests that the physical state of the protein—its ability to form a droplet—is just as important as its genetic sequence. This provides a clear target for future drug development: if a small molecule can be designed to disrupt the coiled-coil interaction or "melt" the droplets, it could potentially neutralize the cancer’s driving force.
Broader Implications for Oncology
While the immediate focus of the study is translocation renal cell carcinoma, the implications resonate across the entire field of oncology. Genetic fusions are a hallmark of many other cancers, including Ewing sarcoma (a bone cancer primarily affecting children and young adults) and various forms of leukemia.
Dr. Cai suggested that the "droplet" mechanism might be a universal feature of fusion-driven cancers. "Other cancers, such as Ewing sarcoma and leukemia, are caused by fusion genes as well," she noted. "It’s possible that these fusion genes form similar droplets, or condensates, that regulate genes in these cancers and could react to similar treatment strategies."
This paradigm shift moves the focus away from trying to inhibit a single protein’s enzymatic activity—which is often difficult with transcription factors like TFE3—and toward disrupting the physical environment (the condensate) that allows these proteins to function. This approach could unlock "undruggable" targets that have frustrated drug developers for decades.
Chronology and Collaborative Support
The findings represent years of interdisciplinary collaboration between biochemists, oncologists, and genomic experts. The project combined the Bloomberg School’s expertise in molecular condensates with the Kimmel Cancer Center’s clinical insights into renal malignancies.
The study, which culminated in the April 22 publication, involved a diverse team of researchers including Choon Leng So, Ye Jin Lee, Wanlu Chen, and others from Johns Hopkins, as well as collaborators from the National Cancer Institute (NCI).
The research was heavily supported by public and private funding, reflecting the high priority placed on finding solutions for rare cancers. Key funding sources included:
- The National Institutes of Health (NIH) National Institute of General Medical Sciences.
- The National Cancer Institute (NCI).
- The Department of Defense (DoD) Kidney Cancer Idea Development Award.
- The National Human Genome Research Institute.
- The Johns Hopkins Provost Catalyst Award.
The Path Forward: From Bench to Bedside
The next phase of the research will involve screening for drugs or small molecules capable of disrupting the TFE3 fusion condensates. Because tRCC is a rare disease, it often does not receive the same level of pharmaceutical investment as more common cancers like lung or breast cancer. However, the discovery of a specific structural vulnerability—the coiled-coil domain—provides a concrete starting point for high-throughput drug screening.
The team also hopes to identify other "passenger" proteins that are drawn into the TFE3 droplets. If these droplets require certain co-factors to remain stable, those co-factors might already have existing inhibitors that could be repurposed for tRCC treatment.
In the landscape of precision medicine, this study stands as a testament to the power of basic science in uncovering the "how" behind the "what." By visualizing the microscopic droplets that orchestrate genetic chaos, the Johns Hopkins team has provided a roadmap for turning a rare, treatable-resistant cancer into a manageable, targeted condition.
As Dr. Cai and Dr. Toska move toward clinical applications, their work serves as a beacon for patients with translocation renal cell carcinoma, who have long waited for a standard of care that addresses the unique molecular drivers of their disease. The study’s success underscores a growing consensus in the scientific community: to stop cancer, we must not only understand the genes involved but also the physical structures they build within the cell.
Leave a Reply